Document Detail


Stentless biological valved conduit for aortic root replacement: Initial experience with the Shelhigh BioConduit model NR-2000C.
MedLine Citation:
PMID:  20832085     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVES: We retrospectively evaluated our results with the Shelhigh biological conduit model NR-2000C (Shelhigh, Inc, Milburn, NJ).
METHODS: From November 1998 through December 2007, 175 patients with a mean age of 71.1 ± 7.4 years underwent aortic root replacement with a Shelhigh biological conduit. Indication for surgery was aneurysmal disease of the aorta in 120 (68.6%) patients, aortic valve endocarditis in 20 (11.4%), acute type A aortic dissection in 11 (6.3%), and other in 24 (13.7%) patients.
RESULTS: Overall hospital mortality was 13.7% (n = 24; 95% confidence limits, 9.0%-19.7%). Cause of death was cardiac failure in 12 patients, central neurologic damage in 5 patients, pulmonary in 3 patients, gastrointestinal ischemia in 2 patients, and aorta-related in 2 patients. Mean follow-up was 3.1 years (range 0.2-9.9 years). In total, 50 (33.1%) late deaths occurred; of these 7 were valve-related. The overall survival at 1 and 5 years is 77.6% ± 3.2% and 54.6% ± 4.6% respectively. Six (4.0%) patients required reoperation, either for endocarditis of the bioconduit (n = 5) or for false aneurysm (n = 1). Endocarditis of the bioconduit was reported in 11 (7.3%) patients, of whom 6 were treated nonoperatively and 5 required reoperation.
CONCLUSIONS: Midterm results of the implantation of the Shelhigh biological valved conduit are worrisome. The relatively high incidence of endocarditis of the Shelhigh BioConduit has forced us to look for other alternatives.
Authors:
Abdullah Kaya; Robin H Heijmen; J C Kelder; Marc A Schepens; Wim J Morshuis
Related Documents :
20845885 - Is early antithrombotic therapy necessary after tissue mitral valve replacement?
15749175 - Superiority of surgical versus medical treatment in patients with staphylococcus aureus...
10678385 - Preliminary experience with silzone-coated st. jude medical valves in acute infective e...
12842515 - A prospective controlled trial of st. jude versus starr edwards aortic and mitral valve...
19329115 - Expectant management of incomplete abortion in the first trimester.
19855355 - The effectiveness of choline citrate infusions monitored by lymphocyte transformation t...
Publication Detail:
Type:  Journal Article     Date:  2010-09-15
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  141     ISSN:  1097-685X     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1157-62     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Affiliation:
Department of Cardiothoracic Surgery, St Antonius Hospital, Nieuwegein, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rapid peripheral arterial cannulation for extracorporeal life support with unimpaired distal perfusi...
Next Document:  Major complications during negative pressure wound therapy in poststernotomy mediastinitis after car...